710 related articles for article (PubMed ID: 18157010)
1. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
2. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
[TBL] [Abstract][Full Text] [Related]
3. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
[TBL] [Abstract][Full Text] [Related]
4. Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.
Sonoda T; Sugimura K; Ikemoto S; Kawashima H; Nakatani T
Oncol Rep; 2007 Jun; 17(6):1469-74. PubMed ID: 17487406
[TBL] [Abstract][Full Text] [Related]
5. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.
O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343
[TBL] [Abstract][Full Text] [Related]
7. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
8. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
De Boer EC; Rooijakkers SJ; Schamhart DH; Kurth KH
J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.
Suttmann H; Riemensberger J; Bentien G; Schmaltz D; Stöckle M; Jocham D; Böhle A; Brandau S
Cancer Res; 2006 Aug; 66(16):8250-7. PubMed ID: 16912205
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of bacillus Calmette-Guérin-induced nitric oxide in bladder tumor cells may improve BCG treatment.
Alvarez V; Lodillinsky C; Umerez S; Sandes E; Eiján AM
Int J Mol Med; 2005 Oct; 16(4):565-71. PubMed ID: 16142388
[TBL] [Abstract][Full Text] [Related]
12. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
Chang SG; Lee SJ; Huh JS; Lee JH
Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
[TBL] [Abstract][Full Text] [Related]
13. Optimizing syngeneic orthotopic murine bladder cancer (MB49).
Günther JH; Jurczok A; Wulf T; Brandau S; Deinert I; Jocham D; Böhle A
Cancer Res; 1999 Jun; 59(12):2834-7. PubMed ID: 10383142
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation.
Udagawa M; Kudo-Saito C; Hasegawa G; Yano K; Yamamoto A; Yaguchi M; Toda M; Azuma I; Iwai T; Kawakami Y
Clin Cancer Res; 2006 Dec; 12(24):7465-75. PubMed ID: 17189420
[TBL] [Abstract][Full Text] [Related]
15. Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer.
Sänger C; Busche A; Bentien G; Spallek R; Jonas F; Böhle A; Singh M; Brandau S
BMC Cancer; 2004 Nov; 4():86. PubMed ID: 15566565
[TBL] [Abstract][Full Text] [Related]
16. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model.
Loskog AS; Fransson ME; Totterman TT
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8816-21. PubMed ID: 16361570
[TBL] [Abstract][Full Text] [Related]
17. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model.
Horinaga M; Harsch KM; Fukuyama R; Heston W; Larchian W
Urology; 2005 Aug; 66(2):461-6. PubMed ID: 16040105
[TBL] [Abstract][Full Text] [Related]
18. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.
Chen F; Zhang G; Cao Y; Hessner MJ; See WA
J Urol; 2009 Dec; 182(6):2932-7. PubMed ID: 19853870
[TBL] [Abstract][Full Text] [Related]
19. Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model.
Hegele A; Dalpke A; Barth P; Varga Z; Heeg K; Hofmann R; Olbert P
Anticancer Res; 2004; 24(4):2225-30. PubMed ID: 15330165
[TBL] [Abstract][Full Text] [Related]
20. CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.
Ninalga C; Loskog A; Klevenfeldt M; Essand M; Tötterman TH
J Immunother; 2005; 28(1):20-7. PubMed ID: 15614041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]